Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

K. A. Fox, S. M. Lippman, J. R. Cassady, R. S. Heusinkveld, Thomas P Miller

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Between 1972 and 1984, 17 patients with advanced Hodgkin's disease failing intensive combination chemotherapy in previously unirradiated nodal and/or pulmonary sites were treated with salvage radiotherapy. Treatment consisted of comprehensive wide field radiotherapy to all known areas of disease. Doses administered to these fields ranged from 1,700 to 5,000 rad, with only three patients (18%) receiving < 3,000 rad to any field. With a median follow-up of over 4 years, 88% achieved a complete response, with median actuarial disease-free survival (DFS) of 19 months (range, 4 to 61 +). Actuarial median survival was 64 months, with a range of 4 to 134+ months. Nine patients (53%) are currently alive with three (18%) in continuous complete remission (CR) for 24, 30 and 61 months. In addition, four patients relapsing after salvage radiotherapy are now in CR following additional therapy. Patients younger than 35 years of age had a significantly increased overall survival when compared with older patients (P<.005). An initial complete response to chemotherapy lasting 12 or more months appeared to be a favorable prognostic factor, although small patient numbers preclude statistical significance. Comprehensive salvage radiotherapy is of significant benefit in patients with advanced Hodgkin's disease relapsing after combination chemotherapy in nodal and/or pulmonary sites.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalJournal of Clinical Oncology
Volume5
Issue number1
Publication statusPublished - 1987
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fox, K. A., Lippman, S. M., Cassady, J. R., Heusinkveld, R. S., & Miller, T. P. (1987). Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. Journal of Clinical Oncology, 5(1), 38-45.